Compare WALD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WALD | CCCC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 240.3M |
| IPO Year | 2021 | 2020 |
| Metric | WALD | CCCC |
|---|---|---|
| Price | $1.93 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.76 | ★ $7.25 |
| AVG Volume (30 Days) | 169.5K | ★ 1.9M |
| Earning Date | 11-24-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $274,560,000.00 | $30,108,000.00 |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | $11.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.22 | N/A |
| 52 Week Low | $1.48 | $1.09 |
| 52 Week High | $4.10 | $4.26 |
| Indicator | WALD | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 34.04 |
| Support Level | $1.73 | $2.00 |
| Resistance Level | $2.01 | $2.69 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 25.33 | 3.55 |
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.